ADMA Biologics, Inc.

ADMA Biologics, Inc.(NASDAQ: ADMA) is a biopharmaceutical business focused on developing, producing, and marketing speciality plasma-based biologics to treat and prevent infectious illnesses.

Key Highlights

• The company reported a growth of 101.24% in total revenue to USD 20.68 million in Q3FY21 (ended September 30, 2021) compared to USD 10.28 million in Q3FY20.
• Net loss for Q3FY21 increased to USD 17.71 million from USD 16.92 million in Q3FY20.
• On November 16, 2021, ADMA began operations and actuation of donor plasma collections at its latest ADMA BioCenters at Myrtle Beach, South Carolina.
• Significantly low gross margin 1.9% in Q3FY21 vs. industry median of 85.4%.
• The Debt/Equity ratio as of Q3FY21 was 0.92x, making a relatively leveraged balance sheet.
• Stock is currently trading below its crucial long-term as well as short-term 50-day and 200-day SMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 1.01 to USD 3.11.
• ADMA's share price has decreased 42.03% and 41.75% in the past nine and twelve months, respectively.

Technical Price Chart (as of December 16, 2021). Analysis by Kalkine

Conclusion: The company's bottom-line performance deteriorated in Q3FY21 compared to the previous comparable period. Given the lackluster fundamentals, a significant correction in the stock price in the past twelve months and lack of visibility in bottom-line growth, we recommend an "Avoid" rating on the stock at the closing price of USD 1.20, down 6.25% as of December 16, 2021.

*The reference data in this report has been partly sourced from REFINITIV.

Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) is a biopharmaceutical business that develops medicines to improve the body's ability to transport oxygen to where it is required. Glioblastoma multiforme (GBM) and metastatic brain cancer are treated with trans sodium crocetinate (TSC), which is the company's lead product candidate.

Key Highlights

• The company has yet to report revenue from its operations.
• Net loss for Q3FY21 increased to USD 12.20 billion from USD 4.44 billion reported in Q3FY20, attributable to USD 8.64 billion from the In-process research and development impairment charge.
• On December 16, 2021, DFFN dosed its first patients in ILD-DLCO Trial. TSC will be tested in patients with previously diagnosed interstitial lung disease (ILD).
• Negative ROE of 27.6% in Q3FY21.
• Stock is currently trading below its crucial short-term as well as long-term 50-day and 200-day SMA support levels, a bearish indicator.
• Stock is currently leaning towards the lower end of the 52-week range of USD 0.34 to USD 1.85.
• DFFN's share price has decreased 50.99% and 65.64% in the past six and nine months, respectively.

Technical Price Chart (as of December 17, 2021). Analysis by Kalkine

Conclusion: The company has not reported revenues to date. Given the lackluster fundamentals, a significant correction in the stock price in the past nine months, and lack of visibility in bottom-line growth, we recommend an "Avoid" rating on the stock at the current price of USD 0.3505, up 1.89% as of December 17, 2021, at 1:19 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.